Nausea Clinical Trial - Efficacy of Aprepitant (Emend®) in Children

Status Completed

Clinical Trial Summary

The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.

Clinical Trial Description

1.1 Primary Aim To determine the efficacy of aprepitant (Emend®) in preventing and reducing chemotherapy-induced nausea and vomiting (CINV) when added to standard antiemetic drug regimens for children receiving highly emetogenic chemotherapy. The working hypothesis will be that standard therapy + aprepitant is superior at preventing CINV than standard therapy + placebo. 1.2 Secondary Aim To evaluate the safety and toxicity of aprepitant (Emend®) in children receiving highly emetogenic chemotherapy when compared to standard antiemetic therapy + placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01661335
Study type	Interventional
Source	University of Oklahoma
Contact
Status	Completed
Phase	Phase 3
Start date	June 1, 2012
Completion date	June 29, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01649258` - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy	Phase 1
Completed	`NCT02939287` - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan	Phase 3
Not yet recruiting	`NCT06464926` - Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)	N/A
Not yet recruiting	`NCT06055192` - Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Recruiting	`NCT04091789` - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea	Phase 2
Completed	`NCT02462811` - A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)	Phase 3
Completed	`NCT01007500` - Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery	Phase 4
Recruiting	`NCT00528554` - Laser Acupuncture Against Nausea in Children	N/A
Completed	`NCT00537875` - Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens	N/A
Completed	`NCT00394966` - A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)	Phase 2
Completed	`NCT00947128` - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions	Phase 1
Completed	`NCT00946387` - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions	Phase 1
Recruiting	`NCT05433636` - Mindful Waiting Room	N/A
Not yet recruiting	`NCT04827108` - Psychometric Properties of the Chinese Version of PeNAT
Not yet recruiting	`NCT04853303` - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK	N/A
Terminated	`NCT04247100` - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders	N/A
Recruiting	`NCT04181346` - Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting	Phase 2
Recruiting	`NCT03679182` - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care	Phase 2
Completed	`NCT02618343` - EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron	N/A
Terminated	`NCT01405924` - Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)	Phase 2